Patients
pulmonary embolism, Renal-Cell Carcinoma, active autoimmune disease, DVT, Tumors, Cancer
PULMONARY EMBOLISM, DEEP VENOUS THROMBOSIS, DISEASE, DVT, TUMORS, ONCOLOGY, VENOUS THROMBOSIS, CANCER
Eligible patients were adults with histologically proven and previously untreated mRCC with a clear cell component. Patients had measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. Patients with any International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic risk score were included. An Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2 as assessed by the investigator and radiographic evidence of metastatic disease/stage IV (American Joint Committee on Cancer, AJCC) were included. Patients with active autoimmune disease, active use of immunosuppressive medications, prior exposure to ICIs or cabozantinib in the adjuvant setting, or symptomatic venous thrombosis were excluded from the study. Incidentally detected asymptomatic deep venous thrombosis (DVT) or pulmonary embolism (PE) on routine scans were allowed if stable and treated with therapeutic anticoagulation for at least 2 weeks before the first dose of therapy.